Ls Investment Advisors, LLC Supernus Pharmaceuticals, Inc. Transaction History

Ls Investment Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$20.2 - $25.05 $36,562 - $45,340	-1,810 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$19.93 - $29.13 $84,443 - $123,423	-4,237 Reduced 70.07%	1,810 $43,000
Q2 2019 Aug 07, 2019	BUY	$29.96 - $38.87 $2,127 - $2,759	71 Added 1.19%	6,047 $200,000
Q1 2019 Apr 25, 2019	BUY	$32.77 - $41.99 $17,794 - $22,800	543 Added 9.99%	5,976 $209,000
Q4 2018 Feb 01, 2019	SELL	$30.84 - $49.51 $15,173 - $24,358	-492 Reduced 8.3%	5,433 $180,000
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $45,219 - $59,886	-1,059 Reduced 15.16%	5,925 $298,000
Q2 2018 Jul 20, 2018	SELL	$44.1 - $59.85 $1,323 - $1,795	-30 Reduced 0.43%	6,984 $418,000
Q1 2018 May 08, 2018	SELL	$37.15 - $46.9 $74 - $93	-2 Reduced 0.03%	7,014 $321,000
Q4 2017 Feb 07, 2018	SELL	$36.4 - $42.6 $77,604 - $90,823	-2,132 Reduced 23.31%	7,016 $280,000
Q3 2017 Oct 19, 2017	BUY	$36.75 - $49.65 $336,189 - $454,198	9,148	9,148 $366,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Ls Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ls Investment Advisors, LLC with notifications on news.